Would you offer adjuvant chemotherapy, osimertinib, or both to a patient with Stage IB EGFR mutated lung adenocarcinoma found in the lung explant pathology after bilateral lung transplant?
Would you consider the immune suppressed status of the patient as a high risk factor to offer adjuvant therapy?
Answer from: Medical Oncologist at Academic Institution
This is such a rare and individualized case that there will likely be no correct answer. My understanding of the facts is that stage IB lung adenocarcinoma was found on the removed explanted lung after a lung transplant. The question posed is what is the role of adjuvant systemic therapy? Ignoring t...
Sign in or Register to read more